Table of Contents Table of Contents
Previous Page  320 / 812 Next Page
Information
Show Menu
Previous Page 320 / 812 Next Page
Page Background

S316

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

of the negative symptoms domains might help refining hypotheses

on their pathophysiological basis.

Aims

The objective of this study was to evaluate, in the con-

text of the multicenter study of the Italian Network for Research

on Psychoses, the relationships between auditory event-related

potentials (ERPs) components and negative symptom domains in

patients with schizophrenia (SCZ).

Methods

We examined ERPs recorded during an auditory odd-

ball task in 115 chronic stabilized SCZ (78% on second-generation

antipsychotics) and 62 matched healthy controls (HC). Negative

symptoms were assessed using the Brief Negative Symptom Scale.

Results

Our main findings included significant N100 and P3b

amplitude reductions in SCZ compared toHC. P3b amplitude didnot

correlate with any negative symptom domain, while N100 ampli-

tude correlated with both anhedonia and avolition domains.

Conclusions

Avolition and anhedonia, often clustering in the

same factor, are related to abnormalities of early components of

the ERPs correlated with perceptual and automatic attention pro-

cesses. None of the negative symptom domains is associated with

abnormalities of the later stages indexed by P3 amplitude.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.687

EW570

Self-Stigma and adherence to

medication in patients with psychotic

disorders – cross-sectional study

K. Vrbova

, D. Kamaradova , K. Latalova , M. Ociskova , J. Prasko ,

B. Mainerova , A. Cinculova , R. Kubinek , A. Tichackova

Faculty of Medicine and Dentistry- Palacky University Olomouc and

University Hos, Department of Psychiatry, Olomouc, Czech Republic

Corresponding author.

Introduction

Adherence to treatment of mental disorders is one

of the key factors influencing its success and, secondarily, the

patients’ quality of life and social adaptation.

Aims

The cross-sectional study of 90 outpatients diagnosed with

psychotic disorders aimed at determining if there was a relation-

ship between discontinuation of medication in the past, current

adherence to treatment and self-stigma.

Methods

The assessment was made with the objective and sub-

jective Clinical Global Impression – Severity scale, Drug Attitude

Inventory, Internalized Stigma of Mental Illness (ISMI) scale and

demographic data.

Results

The questionnaires were filled out by 79 patients, of

whom 5 handed in incomplete questionnaires. Complete sets of

data were obtained from 74 patients. The data analysis showed

that the levels of self-stigma as assessed by the total ISMI scores

was not statistically significantly correlatedwithmost of the demo-

graphic factors (age, age of illness onset, gender, education, marital

status, employment, duration of the illness, number of hospitaliza-

tions and antipsychotic dosage). However, there was a significant

negative correlation with current adherence to treatment.

Conclusions

Adherence to treatment is one of the most impor-

tant prerequisites for successful therapy. Adherence may be

enhanced through better motivation and education of patients

on the necessity of adhering to treatment recommendations and

the consequences of non-adherent behavior. Important factors in

adherence also seem to be patients’ stigmatization and self-stigma.

Adherence may be increased by promising self-stigma-reducing

strategies performed by systematic psychoeducation of patients or

as a part of psychotherapeutic counseling.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.688

EW571

Healthcare resource use of

paliperidone palmitate 3-month

injection vs. paliperidone palmitate

1-month injection: An analysis of

phase III clinical trial hospital data

K. Woodruff

1 ,

, C. Chirila

2

, Q. Zheng

2

, K. Van Impe

3

, I. Nuamah

4

1

Janssen Research & Development - LLC, Global Market Access,

Titusville, USA

2

RTI-Health Solutions, Biostatistics, Research Triangle Park, USA

3

Janssen-Cilag, Market Access, North Brabant, Netherlands

4

Janssen Research & Development - LLC, Biostatistics, Titusville, USA

Corresponding author.

Introduction

PSY-3011 was a randomized, multicenter, double-

blind, non-inferiority study of paliperidone palmitate 3-month

injection (PP3M) vs. paliperidone palmitate 1-month injection

(PP1M). Adults with schizophrenia were stabilized on PP1M in an

open-label (OL) 17-week transition phase. Qualifying subjects at

the end of the OL phase were then randomized to PP3M or PP1M

in the 48-week double-blind (DB) phase. Healthcare resource uti-

lization (HCRU) between PP3M and PP1M was compared using the

HCRU questionnaire during the double-blind (DB) phase.

Methods

HCRU was measured at the start of the OL and DB

phases, and every 12 weeks during DB until end of study/early

withdrawal. Information included hospitalizations, ER visits, day

or night clinic stays, outpatient treatment, daily living conditions,

and occupational status. Logistic regressions modeled the proba-

bility of hospitalization vs. no hospitalization for psychiatric and

social reasons, as well as hospitalizations for psychiatric reasons

only, during the DB phase. The models controlled for OL baseline

hospitalizations, OL phase hospitalizations, and time in study.

Results

The analysis set included 483 subjects randomized to

PP3M and 512 subjects to PP1M during the DB phase. The odds

of hospitalization for psychiatric/social reasons during 1 year for

PP1Msubjects were 1.16 times the odds of hospitalization for PP3M

subjects (95% CI: 0.70, 1.93,

P

= 0.56). For psychiatric reasons only,

the odds of hospitalization during 1 year for PP1M subjects were

1.63 times the odds of hospitalization for PP3M subjects (95% CI:

0.88, 3.02,

P

= 0.12).

Conclusions

PP3Mand PP1Mdemonstrated similar trends in hos-

pitalizations throughout the course of the study.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.689

EW572

The effects of fluvoxamine on

cognition in patients with

schizophrenia

S.M. Zamir

, S.A. Haji Seyed Javadi , Z. Farzaneh Khanshir

Qazvin university of medical sciences, Psychiatry, Qazvin, Iran

Corresponding author.

Introduction

Schizophrenia is a severe disease which affects

different aspects of behavior, including cognitive functions. The

most important fields of cognitive disorders in schizophrenia are

working memory, vigilance/attention, learning by oral and visual

memory, argument and resolving, analysis rate and social knowl-

edge.

Aims

This studywas designed to assess the effects of fluvoxamine

on cognitive functions of schizophrenic patients.

Method

Thirty-six patients with schizophrenia, all male, were

treated with 100mg fluvoxamine and a second generation anti-

psychotic for 4 weeks and before and after treatment, their

cognitive functions were assessed by Wechsler-3 memory scale